Intravesical drug delivery devices that include a device body, a number of solid drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The drug tablets is positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen.

The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

The present invention provides methods for treating an individual having bladder cancer comprising intravesically administering to the individual an oncolytic virus. Also provided are pharmaceutical compositions and kits for treating bladder cancer.

The present disclosure provides pharmaceutical compositions comprising Gamma-glutamyl cycle inhibitors (GGCI) and certain pharmaceutically acceptable salts thereof, and methods of use.

The present invention relates to a biocompatible polydopamine nanomotor capable of infiltrating a bladder wall in a biological environment and remaining inside a bladder for a long time.

The present invention relates to a biocompatible polydopamine nanomotor capable of infiltrating a bladder wall in a biological environment and remaining inside a bladder for a long time.

The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.

Disclosed by the invention is a heterocyclic compound, an intermediate, and a preparation method therefor and an application thereof. Provided by the invention are a heterocyclic compound as shown in formula I, and a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof. The heterocyclic compound has a high P2X3 antagonistic activity, and has good selectivity, low toxicity, good metabolic stability and little taste influence.

##STR00001##

The present invention relates to a method for preparing coumarin compounds substituted by amidoalkyl at 3-position, and related intermediates thereof. The method includes: Step (A): reacting a compound of formula (VI) with a compound of formula (V) to give a compound of formula (VII)

##STR00001## wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen, halogen, and —O(C.sub.1-8 alkyl), wherein the alkyl is optionally substituted with 1 or 2 groups selected from the group consisting of halogen, C.sub.1-8 alkyl substituted with 1-2 hydroxyl groups, —O(C.sub.1-8 alkyl); R.sub.3 is -L-C(O)NR.sub.5R.sub.6, L is C.sub.1-3 alkylene.